Trump Administration’s Shift on Marijuana Classification Sparks Mixed Reactions

The Trump administration, alongside the Justice Department, is taking steps to alter how the federal government classifies marijuana. However, there are varied opinions among Republicans regarding this change in policy.

On Thursday, Acting Attorney General Todd Blanche announced a move to reclassify state-approved medical marijuana. He highlighted that this decision aims to keep “President Trump’s promise” to expand healthcare choices for Americans.

Blanche emphasized that altering the drug’s classification would pave the way for research into its safety and efficacy, which could ultimately enhance patient care and equip doctors with more reliable information.

White House officials indicated that the administration would continue to act quickly on Trump’s December executive order aimed at boosting medical marijuana research, addressing the gap between the current use of medical marijuana and medical intelligence.

DEA Director Terry Cole stated, “Under the guidance of President Trump and Acting Attorney General Blanche, the DEA is speeding up the administrative hearing process, adding much-needed consistency and oversight in an area that has been lacking.” He also noted that law enforcement remains dedicated to combating drug cartels and the fentanyl crisis while safeguarding American lives.

The Justice Department has also revealed updates to streamline the process of moving certain drugs from Schedule I to Schedule III under the Controlled Substances Act. Schedule III includes substances like ketamine, anabolic steroids, and codeine-containing Tylenol. The Biden administration had aimed to adjust marijuana’s classification to Schedule III, but these regulations had not yet been finalized.

It’s important to note that, according to the recent order, any cannabis not covered under an FDA-approved drug or a state medical cannabis license still falls under Schedule I controls, meaning that those handling it face regulatory, civil, and criminal repercussions.

Across the United States, more states are legalizing or broadening the use of medical marijuana. Currently, 24 states and Washington, D.C., permit recreational usage, while 38 states allow it for medical purposes.

However, not all Republicans are on board with this new directive. Rep. Andy Harris (R-Md.), who chairs the Freedom Caucus and is also a physician, expressed concern, stating, “There’s no need to change schedules to conduct medical research on marijuana. All we’re doing is exposing more young people to addictive drugs.”